PHVS - MCAP CO - Pharvaris N.V.

Entry barriers to the rare disease sector are driven by prolonged testing and colossal costs, yet orphan drug status guarantees market exclusivity. Pharvaris N.V. (PHVS) is developing the first oral medication for the treatment of HAE, targeting a narrow patient group. Stable demand for innovation renders the company a defensive asset, independent of crises. Market capitalization reaches 2.25, as confirmed by the current exchange quotes visualized below.

High demand for oral formulations for the therapy of hereditary angioedema forms the valuation foundation for Pharvaris N.V. (PHVS) amid a growing market. By analyzing the company's market capitalization, an investor assesses the aggregate value of all shares, which determines the asset's market resilience to corrections and reveals the level of capital confidence in the issuer's business model regardless of quarterly reporting.